<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00975312</url>
  </required_header>
  <id_info>
    <org_study_id>LEN-TriC-001</org_study_id>
    <nct_id>NCT00975312</nct_id>
  </id_info>
  <brief_title>Solar Lentigines Treatment With the Triple Combination Cream</brief_title>
  <official_title>Solar Lentigines Treatment With the Triple Combination Cream (Hydroquinone 4%, Tretinoin 0.05%, and Fluocinolone Acetonide 0.01%). Randomized, Double Blind, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galderma Laboratories, L.P.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background

        -  Lentigines are usually the first sign of photoaging and may produce a significant impact
           on patients' quality of life.

        -  There is no a treatment of choice for this condition.

        -  Solar lentigines and melasma share similar physiopathologic characteristics.

        -  The triple combination (TC) cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone
           acetonide 0.01%) has been effective and safe for the treatment of melasma and other
           hyperpigmented lesions.

      Hypothesis

      * The TC cream will be effective and safe for the treatment of solar lentigines on the back
      of the hands.

      Patients and methods

        -  22 patients with solar lentigines were selected and their right hand or left hand were
           selected at random to be treated with either TC cream or tretinoin 0.05% cream once
           daily for up 12 weeks.

        -  Patients were instructed to apply both creams on the whole back of the hand and not only
           in the lentigines, and to use a broad-spectrum sunscreen (SPF 50+, UVA-PF 28) daily in
           both hands.

        -  Clinical assessments of Target Lesion Pigmentation, Physician's Global Assessment of
           Improvement and a Subject's Self-Assessment questionnaire were collected for data
           analysis at weeks 4, 8, and 12 after starting the treatment and 3 month post-treatment.

        -  Statistical methods: The ordinally scaled efficacy measures underwent rank
           transformation and were analyzed by analysis of variance to test the null hypothesis of
           no differences among treatments. We performed Mann-Whitney and Wilcoxon tests and the
           XLSTAT 2009 software was used.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion pigmentation becomes equal or slightly darker than the surrounding skin</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in physician's global assessment</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Lentigo</condition>
  <arm_group>
    <arm_group_label>Triple combination cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triple combination cream</intervention_name>
    <description>The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand once daily for up 12 weeks.</description>
    <arm_group_label>Triple combination cream</arm_group_label>
    <other_name>Tri-luma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tretinoin 0.05%</intervention_name>
    <description>Tretinoin 0.05% cream was applied on the whole back of the other hand once daily for up 12 weeks.</description>
    <arm_group_label>Triple combination cream</arm_group_label>
    <other_name>Retacnyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of both sexes of 30 - 80 years of age.

          -  Phototype II-V.

          -  Postmenopausal women of childbearing age or users of any contraception method with
             negative pregnancy test (beta subunit chorionic gonadotropin in the blood) at baseline
             and that maintain the contraceptive treatment during the investigation.

          -  Subjects with more than 10 solar lentigines on the back of each hand wich were no
             treated in the last 6 months

        Exclusion Criteria:

          -  Patients under 30 or over 80 years of age.

          -  Skin types I and VI.

          -  Less than 10 solar lentigines on the back of each hand.

          -  Patients who have received or are receiving any other treatment for lentigines of the
             back of hands.

          -  Women of childbearing age without contraceptive therapy.

          -  Pregnancy or lactation.

          -  History of hypersensitivity to any component of the drugs.

          -  Simultaneous use of other topical skin lightening.

          -  Patient refusal to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William A Romero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emilia M Zegpi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pontificia Universidad Católica de Chile</name>
      <address>
        <city>Santiago</city>
        <zip>6904413</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Fleischer AB Jr, Schwartzel EH, Colby SI, Altman DJ. The combination of 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies. J Am Acad Dermatol. 2000 Mar;42(3):459-67.</citation>
    <PMID>10688717</PMID>
  </reference>
  <reference>
    <citation>Draelos ZD. The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin effectively improves the appearance of solar lentigines in ethnic groups. J Cosmet Dermatol. 2006 Sep;5(3):239-44.</citation>
    <PMID>17177746</PMID>
  </reference>
  <reference>
    <citation>Palumbo A, d'Ischia M, Misuraca G, Prota G. Mechanism of inhibition of melanogenesis by hydroquinone. Biochim Biophys Acta. 1991 Jan 23;1073(1):85-90.</citation>
    <PMID>1899343</PMID>
  </reference>
  <reference>
    <citation>Petit L, Piérard GE. Analytic quantification of solar lentigines lightening by a 2% hydroquinone-cyclodextrin formulation. J Eur Acad Dermatol Venereol. 2003 Sep;17(5):546-9.</citation>
    <PMID>12941090</PMID>
  </reference>
  <reference>
    <citation>Weinstein GD, Nigra TP, Pochi PE, Savin RC, Allan A, Benik K, Jeffes E, Lufrano L, Thorne EG. Topical tretinoin for treatment of photodamaged skin. A multicenter study. Arch Dermatol. 1991 May;127(5):659-65.</citation>
    <PMID>2024983</PMID>
  </reference>
  <reference>
    <citation>Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006 Dec;55(6):1048-65. Epub 2006 Sep 28. Review.</citation>
    <PMID>17097400</PMID>
  </reference>
  <reference>
    <citation>Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol. 2006 May;54(5 Suppl 2):S272-81. Review.</citation>
    <PMID>16631968</PMID>
  </reference>
  <reference>
    <citation>Taylor SC, Torok H, Jones T, Lowe N, Rich P, Tschen E, Menter A, Baumann L, Wieder JJ, Jarratt MM, Pariser D, Martin D, Weiss J, Shavin J, Ramirez N. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003 Jul;72(1):67-72.</citation>
    <PMID>12889718</PMID>
  </reference>
  <reference>
    <citation>Ferreira Cestari T, Hassun K, Sittart A, de Lourdes Viegas M. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol. 2007 Mar;6(1):36-9.</citation>
    <PMID>17348994</PMID>
  </reference>
  <reference>
    <citation>Torok H, Taylor S, Baumann L, Jones T, Wieder J, Lowe N, Jarret M, Rich P, Pariser D, Tschen E, Martin D, Menter A, Weiss J. A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. J Drugs Dermatol. 2005 Sep-Oct;4(5):592-7.</citation>
    <PMID>16167418</PMID>
  </reference>
  <results_reference>
    <citation>Ortonne JP, Pandya AG, Lui H, Hexsel D. Treatment of solar lentigines. J Am Acad Dermatol. 2006 May;54(5 Suppl 2):S262-71. Review.</citation>
    <PMID>16631967</PMID>
  </results_reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2009</study_first_submitted>
  <study_first_submitted_qc>September 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2009</study_first_posted>
  <last_update_submitted>September 10, 2009</last_update_submitted>
  <last_update_submitted_qc>September 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>William Andrés Romero</name_title>
    <organization>Pontificia Universidad Católica de Chile</organization>
  </responsible_party>
  <keyword>lentigo</keyword>
  <keyword>hydroquinone</keyword>
  <keyword>tretinoin</keyword>
  <keyword>fluocinolone acetonide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lentigo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Fluocinolone Acetonide</mesh_term>
    <mesh_term>Hydroquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

